A Randomized, Double-blind, Placebo-controlled Parallel Study of the Tolerability and Efficacy of High Cannabidiol (CBD) Cannabis Extract for the Treatment of Patients With Idiopathic Restless Legs Syndrome (RLS)
Latest Information Update: 17 Nov 2025
At a glance
- Drugs BRC 002 (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions
Most Recent Events
- 05 Nov 2025 Status changed from planning to not yet recruiting.
- 05 Dec 2024 New trial record
- 03 Dec 2024 According to a Biopharmaceutical Research Company media release, the company plans to commence enrollment in this trial by the end of 2025 and is currently seeking input from the FDA on the development plan.